|
Molecules Targeting Inflammatory Signaling
Application
A group of small molecules for treating central and peripheral diseases associated with inflammation.
Key Benefits
Applicable to a wide variety of central nervous system and peripheral diseases.
Can bypass side effects of existing therapeutics targeting similar inflammatory pathways.
High target selectivity and aqueous solubility.
Capability...
Published: 10/15/2025
Contributor(s): Raymond (Ray) Dingledine, Radhika Amaradhi, Shabber Mohammed, Thota Ganesh
|
|
MKK3/MYC Protein-Protein Interaction Inhibitor Overcomes Resistant Non-Small Cell Lung Cancer
Application
A therapeutic use for SGI-1027 in the treatment of Osimertinib-resistant non-small cell lung cancer (NSCLC).
Key Benefits
The MKK3/MYC protein-protein interaction inhibitor SGI-1027 effectively decreases MYC levels in Osimertinib-resistant NSCLC cell lines.
The combination of SGI-1027 with Osimertinib offers synergistic benefits over...
Published: 10/15/2025
Contributor(s): Andrey Ivanov, Haian Fu, Shi-Yong Sun, Zhen Chen
|
|
Assessment of Tumor Response to Treatment Using Level Set Clustering in PET Images
Application
Tumor response algorithm that corrects for anatomical changes and robustly identifies local changes in serial PET images through a clustering algorithm.
Key Benefits
Robust to noise and outliers and can tolerate imperfections in data acquisition.
Could be applicable to many other imaging modalities in radiation therapy.
More accurately...
Published: 2/13/2025
Contributor(s): Timothy Fox, Eduard Schreibmann
|
|
Enhanced Delivery and Efficacy of Antisense Drugs via Covalently Linked Nanodisc Scaffolds
Application
A synthetic nanodisc (ND) scaffold for delivering antisense oligonucleotides (ASOs) for the treatment of disease.
Key Benefits
Improved cellular uptake and protein suppression using antisense oligos.
Longer ASO half-life compared to other ASO delivery methods.
Potential to overcome the delivery and efficacy challenges using ASOs for...
Published: 9/22/2025
Contributor(s): Khalid Salaita, Radhika Sharma
|
|
Optimizing the Engineering of CAR-T Cells
Application
A method for selecting distinct T cell populations in order to generate more effective CAR-T cells.
Key Benefits
The proposed invention focuses on selecting the optimal “starting material” for the engineering CAR-T cells.
This selection method can be utilized for the development of any and all CAR-T therapies, not limited...
Published: 2/13/2025
Contributor(s): Byron Au-Yeung
|
|
Indolium 1 for Advanced Melanoma Treatment
Application
A small molecule compound for the treatment of melanoma.
Key Benefits
Novel small molecule compound for the treatment of resistant melanoma.
Well tolerated in vivo.
Market Summary
Malignant melanoma is a type of skin cancer that begins in melanocyte cells. Melanoma is the 19th most commonly occurring cancer. Exposure to UV radiation...
Published: 7/22/2025
Contributor(s): Jack Arbiser
|
|
Drug Platform for L-Asparaginases for the Treatment of Leukemias
Application
A novel humanized therapeutic L-asparaginase compound to treat acute lymphoblastic leukemia (ALL) and other cancers.
Key Benefits
A novel drug discovery platform for developing asparaginase-based compounds to treat leukemias and other cancers.
The derivatives could exhibit less immunogenicity and systemic toxicity than FDA-approved...
Published: 10/3/2025
Contributor(s): Sunil Raikar, Christopher Doering, H. (Harold) Trent Spencer, Kristopher Knight, Harrison Brown
|
|
Markers Predictive of Therapeutic Response in B-cell Malignancies
Application
Test to detect NF-kB2 breaks to guide treatment with proteasome inhibitors and its use with other therapeutic agents.
Key Benefits
Improved the prediction model to determine which patients are more likely to respond to bortezomib treatment.
Improved the efficacy of treatment for patients with multiple myeloma and lymphomas.
Market...
Published: 9/22/2025
Contributor(s): Leon Bernal-Mizrachi
|
|
Vaccines and Antibody Therapeutics for HPV-related Cancers
Application
Treatment and prevention of HPV-induced malignancies.
Key Benefits
Identification of a protein expressed in a large number of HPV-induced cancers.
Antibodies have been generated that bind to the protein and potentially elicit an immune response to the cancer cells.
The antibodies can be used to develop new treatments and vaccines...
Published: 10/3/2025
Contributor(s): Rafi Ahmed, Andreas Wieland
|
|
Non-invasive Probes to Determine Efficacy of Cancer Therapies
Application
A real-time, non-invasive probe to determine the efficacy of cancer immunotherapies.
Key Benefits
Determines immunotherapy success in patients.
CAR cells can be tested before putting it back in the patients.
Simple diagnostic with readout in 30 minutes compared to 2-3 days.
Market Summary
Lymphoblastic leukemia is one of the most...
Published: 9/22/2025
Contributor(s): Anna Kellner, Khalid Salaita, Curtis Henry
|
